Suchen
Rallybio Corp
RLYBZur Watchlist hinzufügen
15.815USD
-0.125-0.78%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
82.90MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Rallybio Corp Unternehmen
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Rallybio Corp Informationen
BörsenkürzelRLYB
Name des UnternehmensRallybio Corp
IPO-datumJul 29, 2021
CEOUden (Stephen)
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeJul 29
Addresse234 Church Street
StadtNEW HAVEN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl06510
Telefon12038593820
Websitehttps://rallybio.com/
BörsenkürzelRLYB
IPO-datumJul 29, 2021
CEOUden (Stephen)
Führungskräfte von Rallybio Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Mr. Ronald M. (Ron) Hunt
Mr. Ronald M. (Ron) Hunt
Independent Director
Independent Director
--
--
Dr. Lucian Iancovici, M.D.
Dr. Lucian Iancovici, M.D.
Independent Director
Independent Director
--
--
Ms. Christine A. Nash
Ms. Christine A. Nash
Independent Director
Independent Director
--
--
Dr. Hui Liu, Ph.D.
Dr. Hui Liu, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen (Steve) Uden, M.D.
Dr. Stephen (Steve) Uden, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
92.54K
+0.67%
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
4.12K
-0.02%
Ms. Paula Soteropoulos
Ms. Paula Soteropoulos
Independent Director
Independent Director
2.98K
-0.10%
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Dr. Robert (Rob) Hopfner, Ph.D.
Dr. Robert (Rob) Hopfner, Ph.D.
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Rallybio Corp?
Die fünf größten Anteilseigner von Rallybio Corp sind: Dr. Stephen (Steve) Uden, M.D.
Wie viele Institutionen halten Anteile an Rallybio Corp (RLYB)?
Mit Stand vom 2026Q1 halten 138 Institutionen Anteile an Rallybio Corp, mit einem Gesamtmarktwert von etwa 3.48M, was 65.82% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -412366.00 gestiegen.